Report Library
All ReportsDatamonitor Healthcare CV&Met: Chronic Heart Failure Pricing, Reimbursement, and Access
April 13, 2018
Payers were originally extremely worried about the potential cost burden of Entresto, however, the level of concern surrounding the drug is
currently moderate as physician uptake has been lower than expected. Payers suggest that it will take some time for routine prescribing
habits
to change to incorporate Entresto, as physicians have been treating chronic heart failure patients with cheap angiotensin-converting enzyme
inhibitors or angiotensin receptor blockers for many years. If physicians begin requesting Entresto on a frequent basis, then payers across the
US and five major EU markets (France, Germany, Italy, Spain, and the UK) indicate that their approaches to the drug’s reimbursement may
change.
This Datamonitor Healthcare report contains a Pricing & Reimbursement module.
This Datamonitor Healthcare report contains a Pricing & Reimbursement module.
Disease Group Covered: | Cardiovascular |